Answers are grounded in this paper and cite their sources.
Background: Despite the widespread implementation of BRCA1 and BRCA2 and mismatch repair testing, a substantial proportion of patients with suspected hereditary cancer remain without a molecular diagnosis. We evaluated the clinical utility of expanded germline testing in individuals with hereditary breast, ovarian and colorectal cancer susceptibility. Methods: Patients with suspected hereditary breast, ovarian, and colorectal cancer syndromes underwent multigene panel testing using the Ion S5™ System. Pathogenic and likely pathogenic variants were correlated with clinical and histopathological features. Results: Expanded germline testing identified clinically actionable pathogenic variants beyond BRCA1/2 and mismatch repair genes in 13% (146/1126) of high-risk families. Homologous recombination repair genes represented the largest subgroup of findings, with ATM emerging as the most prevalent non-BRCA susceptibility gene (3.7%). Among individuals fulfilling hereditary breast and ovarian cancer criteria, pathogenic variants in Lynch syndrome and polyposis genes were detected in 1.6% of cases, highlighting the limitations of phenotype-driven testing strategies. Additional pathogenic variants were identified in TP53, CDH1, CDKN2A, FANCM, NF1 and NBN, while concurrent mutations were detected in 1.15% of families. Conclusions: These findings demonstrate that a clinically relevant proportion of hereditary cancer susceptibility lies outside the classical BRCA1/2 and mismatch repair gene framework. Incorporating non-canonical susceptibility genes into routine testing increases diagnostic yield, identifies actionable cancer risk alleles and may refine surveillance, prevention and personalised management strategies in high-risk individuals.
No takes yet. Share an insight, caveat, or question.
Arranz-Ledo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: